Current / Ongoing Studies updated July 2020
| No | Study Name/Phase | Type | Sponsor | Population (Gender/Age) | Enrolled / Target | Period |
| 1 | HPV vaccine /Phase III | HPV vaccine | MSD | ♀ 9-26 yrs | 20 | 2010 – 2020 |
| 2 | Menacwy/Phase III | Meningococcal vaccine | Pfizer | ♂/♀ 12-14 M | 86 | 2014 – 2020 |
| 3 | HDT TB/Phase IIb | TB Treatment | Aurum Institute | ♂/♀ 18-65 yrs | 39 | 2016 – 2020 |
| 4 | HVTN 702/Phase IIb | HIV Vaccine | HVTN | ♂/♀18-35 yrs | 483 | 2016 – 2021 |
| 5 | HVTN 705/Phase IIb | HIV Vaccine | Janssen/HVTN | ♀18-35 yrs | 144 | 2018 – 2021 |
| 6 | NC008/Phase IIc | TB Treatment | TB Alliance | ♂/♀≥18 | 33 | 2018 – 2020 |
| 7 | PrEPARE Study/PrEP Rollout | PrEP | RTI | ♀16-24 yrs | n/a | 2019 – 2021 |
| 8 | MV40618/Phase IIIb | Flu treatment (Adults) | Roche | ♂/♀
Index – 12-64 yrs Household – ≥2 yrs |
0 | 2019 – 2020 |
| 9 | EPI RSV | RSV study | GSK | ♀ 18-45 | 100 | 2019 – 2020 |
| 10 | NN9924-4309 (Pioneer 12) | Diabetes (China) | Novo Nordisk | ♂+♀ ≥18 | 2 | 2020 – 2022 |
| 11 | R01 AI147681 KHARITUWE TB STUDY | TB Tracing | John Hopkins University | ♂/♀ 0-99 yrs | Target: 1440 | 2020 – 2025 |
| 12 | SCHIELD PART 2 DCE’s | Behavioural | RTI | ♀18 – 30 | Target: 24 IDI’s,
400 surveys |
2020 – 2021 |
| 13 | ChAdOx1 nCoV-19 | Covid Vaccine | Bill & Melinda Gates and SAMRC | ♂+♀
18-65 |
Target: 400 | 2020 – 2021 |
OUR EXPERIENCE
COVID-19
Areas of Expertise
Completed Projects
Current Projects